I just reported some positive news about Revlimid on Sunday, American Society of Clinical Oncology Recognizes Revlimid As One Of The Year’s “Most Notable Advances.”
I should have also mentioned this Wall Street Journal story: Celgene Raises Price Of Blood Cancer Drug Revlimid By 4.5%.
It has been an up-and-down month for Revlimid. Lots of positive data released at ASH, along with the unfortunate news about how the long term use of Revlimid resulted in an 8% risk of developing secondary cancers.
Up and down? More like a roller coaster ride! Strong research study results highlighting the benefits of using Revlimid for maintenance therapy opens up a huge new market for the drug. Then the unexpected news about leukemia risk and an ill timed price hike announcement.
One can only wonder what the new year will be like for Celgene. Maybe if the news about Revlimid continues to be mixed, the company will push harder for FDA approval of pomalidomide? I wish they would.
Feel good and keep smiling! Pat